Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has greenlit pimicotinib (Pimjetmi), an oral once-daily pill, for adults with symptomatic tenosynovial giant cell tumor (TGCT) when surgery would cause serious harm. In the phase 3 MANEUVER trial, pimicotinib achieved a 56% response rate versus just 3.2% for placebo — and 77% of responders were still responding at 12 months. The drug is expected to be available by mid-November 2026.
The FDA has approved pimicotinib (Pimjetmi) for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) — a rare, locally aggressive tumor of the joint lining — specifically for cases where surgery would worsen functional limitations or cause severe complications. The approval marks a meaningful shift in how clinicians can approach a condition that has historically been viewed as a surgical problem with limited systemic options.
The green light was based on the phase 3 MANEUVER trial, which randomized 94 patients to either pimicotinib 50 mg once daily or placebo. Pimicotinib, an oral CSF-1R kinase inhibitor, significantly outperformed placebo on every key measure — from tumor shrinkage to pain relief to physical function. Experts note this builds on earlier CSF-1R inhibitors like pexidartinib and vimseltinib, with a potentially improved therapeutic profile.
By the Numbers:
Why it matters: For patients with diffuse TGCT who face high surgical risk, pimicotinib offers a durable, once-daily oral option that can downstage disease, relieve symptoms, and potentially spare patients from surgery altogether.